Articles related to TARGETED THERAPIES

Invasive mucinous adenocarcinoma carries elevated NRG1 fusion burden that standard DNA-based sequencing reliably misses, while an FDA-approved targeted therapy now exists for confirmed cases.

The FDA approved vepdegestrant for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after endocrine therapy progression, marking the first regulatory approval of a PROTAC drug.

Extreme LDL-C in young patients with family history points toward familial hypercholesterolemia, a common genetic disorder that remains undiagnosed in 70% of cases.

Daraxonrasib produced 13.2-month median overall survival versus 6.7 months with chemotherapy in 501 previously treated metastatic pancreatic ductal adenocarcinoma patients in the phase 3 RASolute 302 trial.

To help patients and clinicians in strategizing about care decisions at the individual level, ASH convened a multidisciplinary panel — which included experts and patient representatives — to form standardized guidelines for newly diagnosed AML in older patients.

Dr. Rita Rao shares her expert perspective on the goals of neoadjuvant therapy, treatment selection, and the evolving landscape of HER2-targeted strategies.